Global Molybdenum 99 Market Size Likely to Grow at a CAGR of 4.89% By 2035

Global Bio-based Feedstocks market size is predicted to be approx USD 5.17 billion in 2025 and is forecast to reach USD 5.40 billion in 2026 and then approx almost USD 8.33 billion by 2035 with a CAGR of 4.89% over the forecast period 2026 to 2035.

Molybdenum 99 Market Revenue and Trends

Driven by soaring demand for high-quality nuclear medicine imaging technologies and the increasing use of SPECT in diagnosis and treatment worldwide, the market for molybdenum-99 has undergone rapid expansion. Growing numbers of people diagnosed with cardiac diseases, cancers and neurological disorders contribute largely to the high requirement for precise and instantaneous imaging diagnosis and treatment technologies, and molybdenum-99, as a parent of technetium-99m is very essential in this process.

What are the Factors that Significantly Exert an Influence on the development of molybdenum 99 Market?

The increase in need for early and accurate disease diagnosis through nuclear medicine imaging is a key factor driving growth of the molybdenum-99 market. Growing prevalence of various diseases like cardiovascular disorder, cancer and neurological disorder is the cause for the increase in number ofSPECT procedures which further necessitate the use of molybdenum-99, an isotope essential for producing technetium-99m. Moreover, its utility to provide an exact functional visualization of an organ is also assisting in growth of clinical relevance for hospitals and diagnostic centers.

Continuous research and development for enhancement of nuclear medicine and radiopharmaceutical techniques has been the reason for the market growth. Enhancement of the technique for isotope production, efficiency of reactor and radiochemical processing is thereby improving reliability, consistent yield and purity and enhancing the availability of isotopes that has been a historical concern and thus helps in access to diagnostic imaging procedures.

Application in specialized diagnostic areas such as in cardiology imaging, oncology imaging for staging and neurological imaging has also added pace to the molybdenum-99 market. As the dependency of physicians is increasing over the SPECT imaging systems for disease diagnosis at an early stage in these specialties, there will be a continuous increase in demand.

Segment Insight

By Production Method

Reactor-Based Production leads the market

Reactor-based production has a significant share in the market, owing to its existing large-scale production capability and ability to provide a high-purity isotope required for medical nuclear applications on a continual basis. Nuclear research reactors remain the dominant suppliers of Mo-99 on a global scale, providing a vast majority of the demand for technetium-99m generators. Even with aging infrastructures in some areas, these production systems are favored over other alternatives, owing to the reliability and proven supply chain integration for clinical utilization.

Accelerator-based production is the fastest growing segment, attributed to ever-increasing need for diversification in the isotopic supply chain, along with the aim to reduce reliance on nuclear reactors. Cyclotron based production is favored for on-site, local generation in hospital-based centers, allowing for a reduced travel time and constraints for hospitals. The Fission based production by LEU targets is expanding, driven by growing preference towards cleaner, non-proliferation compatible fuel sources.

By Application

Diagnostic imaging (SPECT imaging) dominates the market

Diagnostic imaging (SPECT imaging) leads the molybdenum-99 market by the sheer application volume in the nuclear medicine procedures to evaluate organ functionality. Technetium-99m (daughter isotope of Mo-99) is primarily used for the imaging of cardiac function, bone anomalies and tumor detection which makes it an integral part of nuclear medicine diagnostics. This demand is further amplified with the rising global prevalence of chronic diseases, making SPECT imaging one of the crucial components in medical diagnosis.

Oncology diagnostics and cardiology imaging are among the fastest growing application segments driven by the growing global incidences of cancer and cardiovascular disease, respectively. Neurology imaging is growing steady, supported by the increasing incidences of diseases like Alzheimer's and other neurodegenerative conditions. Bone scanning remains an application that consistently garners stable demand, utilized primarily for fracture detection and assessment of metastatic growths, followed by other applications such as imaging of the kidney and thyroid.

By End-Use

Hospitals dominate the market

Hospitals account for the dominant share of the end-use market for molybdenum-99 owing to the presence of nuclear medicine departments and radiology infrastructure. Most of the SPECT imaging procedures, along with the radiopharmaceutical administration, are carried out in the hospital setting, requiring the assistance of specialized nuclear medicine personnel and state-of-the-art equipment.

Diagnostic imaging centers are the fastest growing segment owing to increasing trends in outsourcing of imaging services and a rising need for freestanding diagnostic facilities. Radiopharmaceutical companies are critical in the isotopic production, distribution and supply chain management. Research institutes rely significantly on molybdenum-99 for clinical research purposes in nuclear medicine while other niche segments like specialty clinics and ambulatory care centers also cater to an increasing share for out-patient diagnoses.

Outlook

According to recent forecasts, the molybdenum-99 market is expected to witness a steady to strong growth between 2026-2035, driven by burgeoning demand for advanced nuclear medicine diagnostics and increasing adoption of SPECT imaging procedures in healthcare worldwide. Growing prevalence of cardiovascular diseases, cancer and neurological disorders is significantly boosting the demand for accurate, early stage diagnosis imaging where molybdenum-99 is crucial for the production of technetium-99m.

Regional Insights

The Asia Pacific region is projected to emerge as the fastest growing market for molybdenum-99 due to rising expenditure on health infrastructure, growing number of healthcare centers and the rapid adoption of advanced diagnostics, all contributing to the increased nuclear medicine demand to tackle diseases like cancer and cardiovascular conditions in countries like China, India, Japan and South Korea.

The North America market continues to remain a significant player in terms of market share due to its highly advanced healthcare infrastructure, high adoption rate of nuclear imaging techniques and extensive research investment for radiopharmaceutical development along with well established supply chains for isotope utilization. The European market for molybdenum-99 is expected to observe steady growth due to well-established health care infrastructure, increasing demand for precise diagnostics, and strong regulatory frameworks in place for nuclear medicine.

Report Scope

Recent Developments

• Curium Pharma plans to grow their network for production and distribution of molybdenum-99 in February 2024 to make the worldwide supply of technetium-99m generators more stable, especially when it comes to nuclear medicine imaging. The aim of the program is to increase the availability of isotopes to hospitals and imaging centers, which has in some areas experienced recurring supply shortages, for example to increase SPECT imaging continuity and also respond to increased need of up-to-date diagnostic service.

List of the prominent players in the Molybdenum 99 Market:

• NRG

• Curium

• NTP Radioisotopes

• ANSTO

• NorthStar Medical Radioisotopes

• SHINE Technologies

• IRE (Institut des Radioéléments / IRE-Elit)

• Lantheus Medical Imaging

• Eckert & Ziegler

• Rosatom State Atomic Energy Corporation

• Others

• ics

• Cardiology Imaging

• Neurology Imaging

• Bone Scanning

• Others

By End-Use

• Hospitals

• Diagnostic Imaging Centers

• Specialty Clinics

• Research Institutes

• Radiopharmaceutical Companies

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America